The Clinical Core is designed to support all VICC breast cancer clinical trials conducted in the SPORE. Its main goals are: a) translate the latest insights of disease biology into rigorously designed SPORE clinical trials;b) streamline biologic sample collection in these clinical trials;c) minimize delays in the activation and promote timely completion of SPORE clinical trials;d) ensure safety of research subjects, adherence to institutional and federal regulatory requirements, and compliance with protocol-specified activities;and e) provide the expertise and manpower to develop, implement, manage and monitor all Breast Cancer SPORE clinical trials (internally and externally - multicentric trials). Over the course of this grant, the Clinical Core will support translational clinical trials coming from: two of the four main projects described in this grant application (projects 1 and 2), future pilot and career development projects, Inter-SPORE and inter-institutional collaborations, aligned with our SPORE. The Clinical Core will work closely with other SPORE Cores and the Clinical Trials Shared Resource of VICC to coordinate all aspects of clinical research, including imaging data extraction, biostatistics support, and biospecimen collection/ processing. The intensive nature of the clinical trials conducted by the SPORE (in terms of precisely timed interventions, the need for coordination of clinical intervention, radiological evaluation, specimen procurement, stabilization, and transport to the Pathology & Tissue Informatics Core, and the need to ensure protection of patients safety and privacy while linking clinical and specimen databases) must be tightly coordinated so that they are done on a consistent schedule, in a consistent fashion, to ensure that information obtained from one patient is comparable to data collected from all the others. Close coordination of clinical, administrative, and research staff activities are required to ensure that the responsibilities and costs for every element of the clinical trial are clearly defined and delineated. In summary, a Clinical Core focused on SPORE related clinical trials is essential for the success of the SPORE, and it has all resources available to achieve the aims outlined in the proposal.
(See Instructions): The Clinical Core will be instrumental in increasing efficiency, minimizing delays and revisions, and maximizing our ability to conduct and complete clinical trials related to the SPORE. Streamlining the clinical trials process assures that these are conducted expeditiously and with the highest degree of scientific rigor, enhancing the SPORE's ability to provide translational research outcomes with tangible clinical benefit.
|Bhola, Neil E; Jansen, Valerie M; Bafna, Sangeeta et al. (2015) Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res 75:405-14|
|Sanders, Melinda E; Schuyler, Peggy A; Simpson, Jean F et al. (2015) Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol 28:662-9|
|Abramson, Vandana G; Lehmann, Brian D; Ballinger, Tarah J et al. (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121:16-Aug|
|Guo, Yan; Zhao, Shilin; Lehmann, Brian D et al. (2014) Detection of internal exon deletion with exon Del. BMC Bioinformatics 15:332|
|Barnes, Stephanie L; Quarles, C Chad; Yankeelov, Thomas E (2014) Modeling the effect of intra-voxel diffusion of contrast agent on the quantitative analysis of dynamic contrast enhanced magnetic resonance imaging. PLoS One 9:e108726|
|Grieb, Brian C; Chen, Xi; Eischen, Christine M (2014) MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res 12:1216-24|
|Su, Pei-Fang; Li, Chung-I; Shyr, Yu (2014) Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Comput Stat Data Anal 74:39-51|
|Bi, Xiaohong; Rexer, Brent; Arteaga, Carlos L et al. (2014) Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. J Biomed Opt 19:025001|
|Jiang, Junfeng; Jia, Peilin; Shen, Bairong et al. (2014) Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget 5:6168-77|
|Jiang, Junfeng; Jia, Peilin; Zhao, Zhongming et al. (2014) Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics 15:1015|
Showing the most recent 10 out of 195 publications